首页 正文

Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti-CD20/CD3 Bispecific Antibody in a Syngeneic B-Cell Malignancy Mouse Model

{{output}}
Introduction: Polatuzumab vedotin (Pola) is an anti-CD79b antibody-drug conjugate. Clinical evidence supports the combination efficacy of Pola with mosunetuzumab or glofitamab, both anti-CD20/CD3 bispecific antibodies (anti-CD20/... ...